Last reviewed · How we verify
Metocurine (dimethyltubocurarinium)
At a glance
| Generic name | dimethyltubocurarinium |
|---|---|
| Sponsor | Eli Lilly |
| Drug class | metocurine |
| Target | Acetylcholine receptor |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
Approved indications
- Muscle relaxation, function
Common side effects
Drug interactions
- neomycin
- netilmicin
- streptomycin
- tobramycin
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Metocurine CI brief — competitive landscape report
- Metocurine updates RSS · CI watch RSS
- Eli Lilly portfolio CI